Fractyl Health, Inc. Common Stock Q3 2025 Earnings Recap

GUTS Q3 2025 November 14, 2025

Get alerts when GUTS reports next quarter

Fractyl Health achieved a significant milestone in Q3 2025 by demonstrating the efficacy of its Revita procedure in maintaining weight loss after the discontinuation of GLP-1 therapy, while also strengthening its financial position for upcoming clinical milestones.

Earnings Per Share Miss

$-0.35 vs $-0.34 est.

-2.9% surprise

Market Reaction

1-Day +12.5%

5-Day +18.75%

30-Day +104.46%

See GUTS alongside your other holdings

Add to your portfolio — free

Key Takeaways

Successfully reported randomized double-blind data indicating sustained weight loss in Revita-treated patients post-GLP-1 therapy, a critical advancement in obesity treatment.
Clinical programs are ahead of schedule, with over 60% of patient randomizations for the pivotal REMAIN one cohort completed.
Upcoming catalysts include six-month data from multiple cohorts and pivotal study results expected in 2026, positioning Revita for potential transformative impact in metabolic medicine.
Real-world studies further validate Revita's efficacy, showing significant weight loss and reductions in HbA1c in patients with type 2 diabetes over extended follow-up periods.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit GUTS on AllInvestView.

Next Q1 2026